Search

Your search keyword '"Riedel, Richard"' showing total 718 results
Start Over Author "Riedel, Richard"
718 results on '"Riedel, Richard"'

251. Class II and class III BRAF mutations in patients with advanced non-small cell lung cancer (NSCLC): Clinical characteristics, mutation patterns, and survival outcomes.

Author

Rasokat, Anna, Kron, Anna, Nogova, Lucia, Siebolts, Udo, Scharpenseel, Heather, Riedel, Richard, Michels, Sebastian Yves Friedrich, Fischer, Rieke Nila, Eisert, Anna, Prang, Darinka, Beckers, Frank, Kambartel, Kato, Kaminsky, Britta, Schaaf, Bernhard, Schulte, Wolfgang, Serke, Monika Heidi, Merkelbach-Bruse, Sabine, Buettner, Reinhard, Wolf, Juergen, and Scheffler, Matthias

Published
2023
Full Text
View/download PDF

252. Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions.

Author

Scharpenseel, Heather, Stickelmann, Andreas, Siemanowski, Janna, Malchers, Florian, Scheffler, Matthias, Hillmer, Axel, Meemboor, Sonja, Merkelbach-Bruse, Sabine, Scheel, Andreas H., Riedel, Richard, Michels, Sebastian Yves Friedrich, Eisert, Anna, Fischer, Rieke Nila, Brodersen, Marlene, Thomas, Roman K., Büttner, Reinhard, Graeven, Ullrich, Kosse, Nils, Nogova, Lucia, and Wolf, Juergen

Published
2023
Full Text
View/download PDF

255. A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).

Author

Grilley-Olson, Juneko E., Allred, Jacob B., Schuetze, Scott, Davis, Elizabeth J., Wagner, Michael J, Poklepovic, Andrew Stewart, Waechter, Blake, Riedel, Richard F., WELLIVER, Meng Xu, Berg, Stephanie A., George, Suzanne, Robinson, Steven Ian, Googe, Paul B., D'Angelo, Sandra P., and Schwartz, Gary K.

Published
2023
Full Text
View/download PDF

256. Primary Meningeal Rhabdomyosarcoma

Author

Palta, Manisha, Riedel, Richard F., Vredenburgh, James J., Cummings, Thomas J., Green, Scott, Chang, Zheng, and Kirkpatrick, John P.

Subjects
Article Subject
Abstract

Primary meningeal rhabdomyosarcoma is a rare primary brain malignancy, with scant case reports. While most reports of primary intracranial rhabdomyosarcoma occur in pediatric patients, a handful of cases in adult patients have been reported in the medical literature. We report the case of a 44-year-old male who developed primary meningeal rhabdomyosarcoma. After developing episodes of right lower extremity weakness, word finding difficulty, and headaches, a brain magnetic resonance imaging (MRI) demonstrated a vertex lesion with radiographic appearance of a meningeal-derived tumor. Subtotal surgical resection was performed due to sagittal sinus invasion and initial pathology was interpreted as an anaplastic meningioma. Re-review of pathology demonstrated rhabdomyosarcoma negative for alveolar translocation t(2;13). Staging studies revealed no evidence of disseminated disease. He was treated with stereotactic radiotherapy with concurrent temozolamide to be followed by vincristine, actinomycin-D, and cyclophosphamide (VAC) systemic therapy.

Published
2011
Full Text
View/download PDF

257. Neutron Scattering Experiment Automation with Python

Author

Zolnierczuk, Piotr A. Ornl and Riedel, Richard A. Ornl

Abstract

The Spallation Neutron Source (SNS) at Oak Ridge National Laboratory currently holds the Guinness World Record as the world most powerful pulsed spallation neutron source. Neutrons scattered off atomic nuclei in a sample yield important information about the position, motions, and magnetic properties of atoms in materials. A neutron scattering experiment usually involves sample environment control (temperature, pressure, etc.), mechanical alignment (slits, sample and detector position), magnetic field controllers, neutron velocity selection (choppers) and neutron detectors. The SNS Data Acquisition System (DAS) consists of real-time sub-system (detector read-out with custom electronics, chopper interface), data preprocessing (soft real-time) and a cluster of control and ancillary PCs. The real-time system runs FPGA firmware and programs running on PCs (C++, LabView) typically perform one task such as motor control and communicate via TCP/IP networks. PyDas is a set of Python modules that are used to integrate various components of the SNS DAS system. It enables customized automation of neutron scattering experiments in a rapid and flexible manner. It provides wxPython GUIs for routine experiments as well as IPython command line scripting. Matplotlib and numpy are used for data presentation and simple analysis. We will present an overview of SNS Data Acquisition System and PyDas architectures and implementation along with the examples of use. We will also discuss plans for future development as well as the challenges that have to be met while maintaining PyDas for 20+ different scientific instruments.

Published
2010

258. Abstract SY36-03: Intraoperative molecular imaging with protease-activated fluorescent imaging agents

Author

Whitley, Melodi J., primary, Cardona, Diana M., additional, Blazer, Dan G., additional, Hwang, Shelley, additional, Greenup, Rachel A., additional, Mosca, Paul J., additional, Cahill, Joan, additional, Mito, Jeffrey K., additional, Cuneo, Kyle C., additional, Larrier, Nicole, additional, O'Reilly, Erin, additional, Spasojevic, Ivan, additional, Riedel, Richard F., additional, Eward, William C., additional, Griffith, Linda G., additional, Bawendi, Moungi G., additional, Ferrer, Jorge, additional, Strasfeld, David B., additional, Lee, W. David, additional, Brigman, Brian, additional, and Kirsch, David G., additional

Published
2015
Full Text
View/download PDF

259. Effects of enhanced caregiver training program on cancer caregiver’s self-efficacy, preparedness, and psychological well-being

Author

Hendrix, Cristina C., primary, Bailey, Donald E., additional, Steinhauser, Karen E., additional, Olsen, Maren K., additional, Stechuchak, Karen M., additional, Lowman, Sarah G., additional, Schwartz, Abby J., additional, Riedel, Richard F., additional, Keefe, Francis J., additional, Porter, Laura S., additional, and Tulsky, James A., additional

Published
2015
Full Text
View/download PDF

261. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.

Author

Burgess, Melissa Amber, primary, Crowley, John, additional, Reinke, Denise K., additional, Riedel, Richard F., additional, George, Suzanne, additional, Movva, Sujana, additional, Van Tine, Brian Andrew, additional, Davis, Lara Emily, additional, Schuetze, Scott, additional, Hu, James, additional, Attia, Steven, additional, Priebat, Dennis A., additional, Reed, Damon R., additional, D'Angelo, Sandra P., additional, Okuno, Scott H., additional, Maki, Robert G., additional, Patel, Shreyaskumar, additional, Baker, Laurence H., additional, and Tawbi, Hussein Abdul-Hassan, additional

Published
2015
Full Text
View/download PDF

262. A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).

Author

Attia, Steven, primary, Riedel, Richard F., additional, Robinson, Steven Ian, additional, Conry, Robert Martin, additional, Sankhala, Kamalesh Kumar, additional, Seon, Ben K., additional, Alvarez, Delia, additional, Adams, Bonne J., additional, Theuer, Charles P., additional, and Maki, Robert G., additional

Published
2015
Full Text
View/download PDF

263. Soft Tissue Sarcoma: Clinical Practice Guidelines in Oncology

Author

Demetri, George D., Antonia, Scott, Benjamin, Robert S., Bui, Marilyn M., Casper, Ephraim S., Conrad, Ernest U., DeLaney, Thomas F., Ganjoo, Kristen N., Heslin, Martin J., Hutchinson, Raymond J., Kane, John M., Letson, G. Douglas, McGarry, Sean V., O’Donnell, Richard J., Paz, I. Benjamin, Pfeifer, John D., Pollock, Raphael E., Randall, R. Lor, Riedel, Richard F., Schupak, Karen D., Schwartz, Herbert S., Thornton, Katherine, von Mehren, Margaret, and Wayne, Jeffrey

Subjects
Clinical Trials as Topic, Radiotherapy, Humans, Antineoplastic Agents, Sarcoma, Soft Tissue Neoplasms, Combined Modality Therapy, Article
Published
2005

264. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide

Author

Günther Hochhaus, José M. Masso, Hatzelmann Armin, Riedel Richard, Dietrich Häfner, Degenhard Marx, Daniela S. Bundschuh, Beate Schmidt, and Michael Stoeck

Subjects
Budesonide, CD4-Positive T-Lymphocytes, Male, medicine.medical_specialty, CD3 Complex, Administration, Topical, Anti-Inflammatory Agents, Administration, Oral, Antineoplastic Agents, Ciclesonide, Pharmacology, Bradykinin, Rats, Sprague-Dawley, chemistry.chemical_compound, Glucocorticoid receptor, Receptors, Glucocorticoid, In vivo, Pregnenediones, Internal medicine, medicine, Concanavalin A, Potency, Animals, Humans, Glucocorticoids, Lung, Active metabolite, Binding Sites, Granuloma, Neoplasms, Experimental, In vitro, Rats, Trachea, Endocrinology, chemistry, Leukocytes, Mononuclear, Molecular Medicine, Cytokines, Interleukin-4, Interleukin-5, Glucocorticoid, Cell Division, Neoplasm Transplantation, Spleen, medicine.drug
Abstract

The glucocorticoid ciclesonide is the 2'R-epimer of 2'-cyclohexyl-11beta-hydroxy-21-isobutyryloxy-16bH-dioxolo[5',4':16,17]pregna-1,4-diene-3,20-dione. The active metabolite desisobutyryl-ciclesonide (des-CIC) is derived from ciclesonide by esterase cleavage of isobutyrate at the C21 position. The relative binding affinities at the rat glucocorticoid receptor were dexamethasone, 100; ciclesonide, 12; des-CIC, 1212; and budesonide, 905. Des-CIC potently inhibited the activation of murine and human lymphocytes in a series of different in vitro systems. With the exception of concanavalin A-stimulated rat spleen cells, des-CIC was more potent than the parent compound. Des-CIC compared well with budesonide in all in vitro systems. Furthermore, the respective 2'S-epimers were always significantly less potent than the 2'R-epimers. In vivo, ciclesonide (intratracheal administration), des-CIC, and budesonide inhibited antigen-induced accumulation of eosinophils, protein, and tumor necrosis factor-alpha into the bronchoalveolar lavage fluid of ovalbumin-sensitized and -challenged Brown Norway rats with an ED(50) value ranging from 0.4 to 1.3 mg/kg, indicating similar potency, which suggests in vivo activation of the parent compound. Ciclesonide and budesonide inhibited the bradykinin-induced protein leakage into the rat trachea. In the rat cotton pellet model, ciclesonide inhibited granuloma formation (ED(50):= of 2 microg/pellet), whereas budesonide and des-CIC were 15- and 20-fold less active; thymus involution was induced with an ED(50) of 303, 279, and 154 microg/pellet, respectively. When applied orally to rats for 28 days, ciclesonide showed low potency in reducing weight of thymus and adrenals, suggesting low oral bioavailability. The in vivo data on ciclesonide highlight its effective local action and a reduced potential for side effects.

Published
2004

267. Gastrointestinal Stromal Tumors, Version 2.2014

Author

von Mehren, Margaret, primary, Randall, R. Lor, additional, Benjamin, Robert S., additional, Boles, Sarah, additional, Bui, Marilyn M., additional, Casper, Ephraim S., additional, Conrad, Ernest U., additional, DeLaney, Thomas F., additional, Ganjoo, Kristen N., additional, George, Suzanne, additional, Gonzalez, Ricardo J., additional, Heslin, Martin J., additional, Kane, John M., additional, Mayerson, Joel, additional, McGarry, Sean V., additional, Meyer, Christian, additional, O’Donnell, Richard J., additional, Pappo, Alberto S., additional, Paz, I. Benjamin, additional, Pfeifer, John D., additional, Riedel, Richard F., additional, Schuetze, Scott, additional, Schupak, Karen D., additional, Schwartz, Herbert S., additional, Van Tine, Brian A., additional, Wayne, Jeffrey D., additional, Bergman, Mary Anne, additional, and Sundar, Hema, additional

Published
2014
Full Text
View/download PDF

268. A phase I study of the safety and activation of a cathepsin-activatable fluorescent cancer-specific probe LUM015.

Author

Whitley, Melodi Javid, primary, Cardona, Diana M., additional, Blazer, Dan G., additional, Hwang, Shelley E., additional, Mosca, Paul J., additional, Cahill, Joan, additional, Ferrer, Jorge M., additional, Strasfeld, David B., additional, Mito, Jeffrey K., additional, Cuneo, Kyle C., additional, Larrier, Nicole, additional, Williams, Nerissa, additional, Spasojevic, Ivan, additional, Riedel, Richard F., additional, Eward, William, additional, Lee, W. David, additional, Griffith, Linda G., additional, Bawendi, Moungi, additional, Kirsch, David G., additional, and Brigman, Brian E., additional

Published
2014
Full Text
View/download PDF

269. Soft Tissue Sarcoma, Version 2.2014

Author

von Mehren, Margaret, primary, Randall, R. Lor, additional, Benjamin, Robert S., additional, Boles, Sarah, additional, Bui, Marilyn M., additional, Casper, Ephraim S., additional, Conrad, Ernest U., additional, DeLaney, Thomas F., additional, Ganjoo, Kristen N., additional, George, Suzanne, additional, Gonzalez, Ricardo J., additional, Heslin, Martin J., additional, Kane, John M., additional, Mayerson, Joel, additional, McGarry, Sean V., additional, Meyer, Christian, additional, O’Donnell, Richard J., additional, Pappo, Alberto S., additional, Paz, I. Benjamin, additional, Pfeifer, John D., additional, Riedel, Richard F., additional, Schuetze, Scott, additional, Schupak, Karen D., additional, Schwartz, Herbert S., additional, Van Tine, Brian A., additional, Wayne, Jeffrey D., additional, Bergman, Mary Anne, additional, and Sundar, Hema, additional

Published
2014
Full Text
View/download PDF

271. Cross Species Genomic Analysis Identifies a Mouse Model as Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma

Author

Koch Institute for Integrative Cancer Research at MIT, Jacks, Tyler E., Kirsch, David G., Mukherjee, Sayan, Lev, Dina, Brigman, Brian E., Yoon, Sam S., Hornicek, Francis J., Eward, William C., Stangenberg, Lars, Dodd, Rebecca D., Lazar, Alexander J., Lahat, Guy, Dodd, Leslie, Riedel, Richard F., Mito, Jeffrey K., Jacks, Tyler E, Koch Institute for Integrative Cancer Research at MIT, Jacks, Tyler E., Kirsch, David G., Mukherjee, Sayan, Lev, Dina, Brigman, Brian E., Yoon, Sam S., Hornicek, Francis J., Eward, William C., Stangenberg, Lars, Dodd, Rebecca D., Lazar, Alexander J., Lahat, Guy, Dodd, Leslie, Riedel, Richard F., Mito, Jeffrey K., and Jacks, Tyler E

Abstract

Undifferentiated pleomorphic sarcoma/Malignant Fibrous Histiocytoma (MFH) is one of the most common subtypes of human soft tissue sarcoma. Using cross species genomic analysis, we define a geneset from the LSL-Kras[superscript G12D]; Trp53[superscript Flox/Flox] mouse model of soft tissue sarcoma that is highly enriched in human MFH. With this mouse geneset as a filter, we identify expression of the RAS target FOXM1 in human MFH. Expression of Foxm1 is elevated in mouse sarcomas that metastasize to the lung and tissue microarray analysis of human MFH correlates overexpression of FOXM1 with metastasis. These results suggest that genomic alterations present in human MFH are conserved in the LSL-Kras[superscript G12D]; p53[superscript Flox/Flox] mouse model of soft tissue sarcoma and demonstrate the utility of this pre-clinical model.

Published
2010

274. Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

Author

Demetri, George D., primary, Chawla, Sant P., additional, Ray-Coquard, Isabelle, additional, Le Cesne, Axel, additional, Staddon, Arthur P., additional, Milhem, Mohammed M., additional, Penel, Nicolas, additional, Riedel, Richard F., additional, Bui-Nguyen, Binh, additional, Cranmer, Lee D., additional, Reichardt, Peter, additional, Bompas, Emmanuelle, additional, Alcindor, Thierry, additional, Rushing, Daniel, additional, Song, Yang, additional, Lee, Ruey-min, additional, Ebbinghaus, Scot, additional, Eid, Joseph E., additional, Loewy, John W., additional, Haluska, Frank G., additional, Dodion, Pierre F., additional, and Blay, Jean-Yves, additional

Published
2013
Full Text
View/download PDF

279. Lung.

Author

Kelsey, Christopher R., Vujaskovic, Zeljko, Jackson, Isabel Lauren, Riedel, Richard F., and Marks, Lawrence B.

Published
2014
Full Text
View/download PDF

282. Soft Tissue Sarcoma, Version 2.2012

Author

von Mehren, Margaret, primary, Benjamin, Robert S., additional, Bui, Marilyn M., additional, Casper, Ephraim S., additional, Conrad, Ernest U., additional, DeLaney, Thomas F., additional, Ganjoo, Kristen N., additional, George, Suzanne, additional, Gonzalez, Ricardo, additional, Heslin, Martin J., additional, Kane, John M., additional, Mayerson, Joel, additional, McGarry, Sean V., additional, Meyer, Christian, additional, O'Donnell, Richard J., additional, Paz, Benjamin, additional, Pfeifer, John D., additional, Pollock, Raphael E., additional, Randall, R. Lor, additional, Riedel, Richard F., additional, Schuetze, Scott, additional, Schupak, Karen D., additional, Schwartz, Herbert S., additional, Shankar, Sridhar, additional, Van Tine, Brian A., additional, Wayne, Jeffrey, additional, Sundar, Hema, additional, and McMillian, Nicole R., additional

Published
2012
Full Text
View/download PDF

284. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors

Author

Vlahovic, Gordana, primary, Meadows, Kellen L., additional, Uronis, Hope E., additional, Morse, Michael A., additional, Blobe, Gerard C., additional, Riedel, Richard F., additional, Zafar, S. Yousuf, additional, Alvarez-Secord, Angeles, additional, Gockerman, Jon, additional, Starodub, Alexander N., additional, Ready, Neal E., additional, Anderson, Elizabeth L., additional, Bendell, Johanna C., additional, and Hurwitz, Herbert I., additional

Published
2012
Full Text
View/download PDF

285. Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.

Author

Blay, Jean-Yves, primary, Chawla, Sant P., additional, Ray-Coquard, Isabelle, additional, Cesne, Axel Le, additional, Staddon, Arthur P., additional, Milhem, Mohammed M., additional, Penel, Nicolas, additional, Riedel, Richard F., additional, Bui Nguyen, Binh, additional, Cranmer, Lee D., additional, Reichardt, Peter, additional, Bompas, Emmanuelle, additional, Alcindor, Thierry, additional, Rushing, Daniel A., additional, Song, Yang, additional, Ebbinghaus, Scot, additional, Haluska, Frank G., additional, Dodion, Pierre F., additional, and Demetri, George D., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results